Published in Oncology Business Week, January 29th, 2006
"Since September we have announced preliminary phase II data on AS1404, reported additional clinical findings on AS1411 and strengthened our balance sheet through a GBP6.55 million share placing," noted Edwards.
Of the company's clinical pipeline developments, Edwards said:
"In October we announced promising preliminary findings from our phase II study of AS1404 in lung cancer. At that time, initial data were available from 47 patients, of whom 23...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week